• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Jumps 250 Points; Tyson Foods Posts Downbeat Results

    8/7/23 9:50:18 AM ET
    $MF
    $QSI
    $SAGE
    $SVFD
    Other Specialty Stores
    Consumer Discretionary
    Industrial Machinery/Components
    Industrials
    Get the next $MF alert in real time by email

    U.S. stocks were higher this morning, with the Dow Jones gaining more than 250 points on Monday.

    Following the market opening Monday, the Dow traded up 0.77% to 35,334.81 while the NASDAQ rose 0.42% to 13,967.81. The S&P 500, also rose, gaining, 0.64% to 4,506.68.

    Check This Out: Merck, Delta Air Lines And 2 Other Stocks Insiders Are Selling

     

    Leading and Lagging Sectors

    • Communication services shares jumped by 1% on Monday.
    • In trading on Monday, consumer discretionary shares rose by just 0.3%.

     

    Top Headline

    Tyson Foods, Inc. (NYSE:TSN) reported worse-than-expected third-quarter financial results.

    Tyson Foods posted adjusted earnings of 15 cents per share, missing market expectations of 34 cents per share. The company’s quarterly sales came in at $13.14 billion, versus estimates of $13.78 billion.

     

    Equities Trading UP

    • Vistagen Therapeutics, Inc. (NASDAQ:VTGN) shares shot up 911% to $16.99 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol met the primary and secondary endpoints.
    • Shares of Save Foods, Inc. (NASDAQ:SVFD) got a boost, shooting 80% to $1.15 on abnormally-high volume.
    • Missfresh Limited (NASDAQ:MF) shares were also up, gaining 48% to $2.9399 on continued upward momentum after the company last week announced entry of share purchase agreements for financing and business acquisition. Also, the company today announced it entered into a share transfer agreement with Freshking Limited.

     

    Equities Trading DOWN

    • Sage Therapeutics, Inc. (NASDAQ:SAGE) shares dropped 48% to $18.81 after the company announced the FDA issued a Complete Response Letter for the New Drug Application for zuranolone in the treatment of adults with major depressive disorder.
    • Shares of Tivic Health Systems, Inc. (NASDAQ:TIVC) were down 39% to $0.0438 after the company priced $1.4 million public offering of 33.17 million shares at $0.041 per share.
    • Quantum-Si incorporated (NASDAQ:QSI) was down, falling 30% to $2.36 after the company reported worse-than-expected second-quarter sales results.

    Also Check This Out: Top 5 Industrials Stocks That May Explode This Month

     

    Commodities

    In commodity news, oil traded down 0.8% to $82.17 while gold traded down 0.1% at $1,973.70.

    Silver traded down 0.7% to $23.555 on Monday while copper fell 0.2% to $3.8585.

     

    Euro zone

    European shares were mixed today. The eurozone’s STOXX 600 rose 0.1%, London’s FTSE 100 fell 0.3% while Spain’s IBEX 35 Index fell 0.2% The German DAX declined 0.1% French CAC 40 rose 0.1% and Italy’s FTSE MIB Index declined 0.1%.

    The Halifax house price index in the UK declined by 2.4% year-over-year in July following a 2.6% fall in June. Industrial production in Germany fell by 1.5% month-over-month in June.

     

    Asia Pacific Markets

    Asian markets closed mixed on Monday, with Japan’s Nikkei 225 rising 0.19%, China’s Shanghai Composite Index falling 0.59% and Hong Kong’s Hang Seng Index declining 0.01%. India’s S&P BSE Sensex, meanwhile, rose 0.3%.

    China's foreign exchange reserves increased to $3.204 trillion at the end of July compared to $3.193 trillion in the previous month. Foreign exchange reserves in Singapore rose to SGD 452.5 billion in July from SGD 448.25 billion a month ago, while foreign exchange reserves in Hong Kong climbed to $421.6 billion in July.

    The index of leading economic indicators in Japan fell to 108.9 in June versus a revised reading of 109.1 in the prior month, while index of coincident economic indicators increased to 115.2 in June versus a final 114.3. Reserve assets in Japan rose to $1.254 trillion in July versus $1.247 trillion in the prior month.

     

    Economics

    Data on consumer credit will be released at 3:00 p.m. ET.

    Now Read This: This Analyst With 83% Accuracy Rate Sees Around 25% Upside In Amazon.com - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts

     

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 107,564,390 cases with around 1,170,780 deaths. India confirmed a total of at least 44,995,980 cases and 531,910 deaths, while France reported over 40,138,560 COVID-19 cases with 167,640 deaths. In total, there were at least 692,636,680 cases of COVID-19 worldwide with more than 6,905,360 deaths.

    Get the next $MF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MF
    $QSI
    $SAGE
    $SVFD

    CompanyDatePrice TargetRatingAnalyst
    Tyson Foods Inc.
    $TSN
    4/6/2026$75.00Neutral → Overweight
    Piper Sandler
    Tyson Foods Inc.
    $TSN
    3/26/2026$72.00Outperform
    Mizuho
    Tyson Foods Inc.
    $TSN
    1/8/2026$67.00Market Perform → Outperform
    BMO Capital Markets
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$0.90Buy → Hold
    Jefferies
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Buy → Hold
    Maxim Group
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Outperform → Mkt Perform
    William Blair
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$1.00Buy → Hold
    Stifel
    Tyson Foods Inc.
    $TSN
    8/20/2025$60.00Neutral
    Analyst
    More analyst ratings

    $MF
    $QSI
    $SAGE
    $SVFD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model

    Ticker Symbol to Change from TIVC to VBIO Effective April 28, 2026; Company Advancing Entolimod™ Toward BARDA Funding and Strategic National Stockpile Procurement While Velocity Bioworks CDMO Builds Independent Revenue BaseSAN ANTONIO, April 23, 2026 /PRNewswire/ -- Tivic Health Systems, Inc. (NASDAQ:TIVC) today announced it is changing its corporate name to Valion Bio, Inc. and its Nasdaq ticker symbol from TIVC to VBIO, effective at market open on Tuesday, April 28, 2026. The CUSIP number for the company's common stock will remain unchanged. The rebrand is not merely cosmetic.

    4/23/26 4:05:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Vistagen Receives FDA "Study May Proceed" Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced receipt of a "Study May Proceed" letter from the U.S. Food and Drug Administration (FDA) under its U.S. Investigational New Drug (IND) application for refisolone nasal spray, the Company's non-hormonal, non-systemic product candidate in Phase 2 development for treatment of moderate to severe vasomotor symptoms (VMS) (also known as "hot flashes") due to menopause. The FDA's Study May Proceed letter enables the Company to pursue further Phase 2 clinical develo

    4/22/26 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum-Si to Report First Quarter 2026 Financial Results on May 7, 2026

    Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will report financial results for the first quarter 2026 on Thursday, May 7, 2026. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individua

    4/16/26 8:30:00 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    $MF
    $QSI
    $SAGE
    $SVFD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 4, 2023 - La FDA aprueba el primer tratamiento oral para la depresión posparto

    For Immediate Release: August 04, 2023 El día de hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó Zurzuvae (zuranolona), el primer medicamento oral indicado para tratar la depresión posparto (DPP) en mujeres adultas. La DPP es un episodio depresivo grave que generalmente ocurre después del parto, pero también puede comenzar durante las últimas etapas

    8/8/23 9:34:19 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 4, 2023 - FDA Approves First Oral Treatment for Postpartum Depression

    For Immediate Release: August 04, 2023 Today, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health

    8/4/23 6:50:31 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MF
    $QSI
    $SAGE
    $SVFD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tyson Foods upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Tyson Foods from Neutral to Overweight and set a new price target of $75.00

    4/6/26 8:41:19 AM ET
    $TSN
    Meat/Poultry/Fish
    Consumer Staples

    Mizuho initiated coverage on Tyson Foods with a new price target

    Mizuho initiated coverage of Tyson Foods with a rating of Outperform and set a new price target of $72.00

    3/26/26 8:52:50 AM ET
    $TSN
    Meat/Poultry/Fish
    Consumer Staples

    Tyson Foods upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded Tyson Foods from Market Perform to Outperform and set a new price target of $67.00

    1/8/26 8:14:43 AM ET
    $TSN
    Meat/Poultry/Fish
    Consumer Staples

    $MF
    $QSI
    $SAGE
    $SVFD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Keyes Jeffry R.

    4 - Quantum-Si Inc (0001816431) (Issuer)

    4/22/26 5:09:09 PM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    SEC Form 4 filed by Hawkins Jeffrey Alan

    4 - Quantum-Si Inc (0001816431) (Issuer)

    4/22/26 5:02:10 PM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    SEC Form 4 filed by Bolton Sheryle

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    4/20/26 4:02:04 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MF
    $QSI
    $SAGE
    $SVFD
    SEC Filings

    View All

    Tivic Health Systems Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

    4/23/26 4:36:54 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 144 filed by Quantum-Si Incorporated

    144 - Quantum-Si Inc (0001816431) (Subject)

    4/22/26 4:50:07 PM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    SEC Form 144 filed by Quantum-Si Incorporated

    144 - Quantum-Si Inc (0001816431) (Subject)

    4/22/26 4:48:00 PM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    $MF
    $QSI
    $SAGE
    $SVFD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dowdy Paula bought $104,450 worth of shares (109,890 units at $0.95), increasing direct ownership by 69% to 269,107 units (SEC Form 4)

    4 - Quantum-Si Inc (0001816431) (Issuer)

    3/9/26 6:01:13 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    Director Kummeth Charles R. bought $459,800 worth of shares (500,000 units at $0.92), increasing direct ownership by 141% to 855,000 units (SEC Form 4)

    4 - Quantum-Si Inc (0001816431) (Issuer)

    3/9/26 6:01:59 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    Chief Financial Officer Keyes Jeffry R. bought $43,465 worth of shares (50,000 units at $0.87), increasing direct ownership by 13% to 446,820 units (SEC Form 4)

    4 - Quantum-Si Inc (0001816431) (Issuer)

    8/13/24 6:01:25 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    $MF
    $QSI
    $SAGE
    $SVFD
    Financials

    Live finance-specific insights

    View All

    Quantum-Si to Report First Quarter 2026 Financial Results on May 7, 2026

    Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will report financial results for the first quarter 2026 on Thursday, May 7, 2026. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individua

    4/16/26 8:30:00 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    Tyson Foods Announces Second Quarter Earnings Conference Call and Webcast

    SPRINGDALE, Ark., April 08, 2026 (GLOBE NEWSWIRE) -- Tyson Foods, Inc. (NYSE:TSN) will release second quarter 2026 financial results on Monday, May 4, 2026. Management will host a conference call and webcast beginning at 9:00 a.m. Eastern Time (8:00 a.m. Central Time). A press release and supplemental materials will be issued before the market opens that morning. WebcastA link for the webcast of the conference call will be available on the Tyson Investor Relations website: https://ir.tyson.com. Audio OnlyParticipants may join the audio-only version of the conference call by calling:Dial In (Toll Free): 1-844-890-1795International Dial In: 1-412-717-9589Please note: All dial-in participan

    4/8/26 4:05:00 PM ET
    $TSN
    Meat/Poultry/Fish
    Consumer Staples

    Quantum-Si Reports Fourth Quarter and Full Year 2025 Financial Results

    Releases List Price of Proteus™ Platform Reiterates Proteus Development Program On Track for Year End 2026 Launch Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced financial results for the fourth quarter and full year ended December 31, 2025. Press Release Highlights Reported fourth quarter revenue of $451,000 Reported on track development of the Proteus platform and related R&D programs to expand proteome coverage and enable broad PTM analysis capabilities Announced list price for Proteus of $425,000 Announced 2026 Financial Guidance

    3/3/26 4:05:00 PM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    $MF
    $QSI
    $SAGE
    $SVFD
    Leadership Updates

    Live Leadership Updates

    View All

    Tyson Foods to Hold Annual Meeting of Shareholders

    SPRINGDALE, Ark., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Tyson Foods, Inc. (NYSE:TSN) will hold its Annual Meeting of Shareholders on Thursday, February 5, 2026 at 11:00 a.m. Eastern time (10 a.m. Central time) at Tyson Foods, 2008 South Thompson Street, Springdale, Arkansas 72764. For shareholders attending in person, an admission ticket is required. Cameras, video and audio recording equipment, as well as large bags are not permitted. Please see our proxy statement, filed on December 17, 2025, for further information. WebcastA link for the webcast of the meeting is available on the Tyson Investor Relations website at https://ir.tyson.com. Audio OnlyParticipants may join the audio-only versi

    1/12/26 4:15:00 PM ET
    $TSN
    Meat/Poultry/Fish
    Consumer Staples

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Vistagen Appoints Paul Edick to its Board of Directors

    Mr. Edick brings extensive industry experience across product development, commercial launch, and growth strategy Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Mr. Paul Edick to its Board of Directors ("Board"). Following the appointment of Mr. Edick, Vistagen's Board will be comprised of seven directors. Mr. Edick will serve on the Audit Committee and the Compensation Committee of the Board. "We are pleased to welcome Mr. Edick to our Board of Directors," said Maggie FitzPatrick,

    10/29/25 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MF
    $QSI
    $SAGE
    $SVFD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

    SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

    11/14/24 6:14:58 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.

    SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

    11/14/24 5:05:41 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.

    SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

    11/14/24 4:19:46 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care